TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Sees Significant Decrease in Short Interest

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 3,800 shares, a decrease of 98.8% from the January 15th total of 318,300 shares. Based on an average daily volume of 104,400 shares, the short-interest ratio is currently 0.0 days.

TC Biopharm Stock Down 18.6 %

TCBP stock traded down $0.64 during trading on Thursday, reaching $2.79. 6,275,201 shares of the stock were exchanged, compared to its average volume of 282,603. TC Biopharm has a twelve month low of $2.72 and a twelve month high of $523.20. The stock has a 50 day simple moving average of $8.06 and a 200-day simple moving average of $43.47.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their target price on TC Biopharm from $112.00 to $48.00 and set a “buy” rating for the company in a report on Friday, December 6th.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.